No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Hutchmed to Receive $10 Million Milestone Payment Through Takeda
Express News | Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance
Hutchmed (China) (00013.HK): Following the first inclusion of FRUZAQLA (fruquintinib) in the healthcare insurance in Europe, a milestone payment from Takeda will be received.
Gelonghui reports on December 13 that Hutchmed (China) (00013.HK) announced it will receive a $10 million milestone payment from its partner Takeda (TSE: 4502/NYSE: TAK). Takeda has received a recommendation in December 2024 for FRUZAQLA to be included in public medical coverage for patients with previously treated metastatic colorectal cancer in Spain, marking the first recommendation for public medical coverage obtained in Europe. Colorectal cancer is the second leading cause of cancer-related deaths in Europe. FRUZAQLA received approval from the European Commission in June 2024.
